Abstract. Chidamide, the structural analog of MS-275, is a novel and promising histone deacetylase (HDAC) inhibitor for use in cancer therapy. To investigate its effects on cancer cell growth, MTT assay was performed in 10 human cancer cell lines. The data showed that the IC 50 of Chidamide ranged from 1 to 13 µM, which was comparable to that of MS-275 in half of the tested cell lines. Furthermore, the growth curve indicated that cell growth was gradually inhibited with an increase in Chidamide dosage, and the inhibition was reversed after drug removal in two hepatocelluclar carcinoma cell lines, BEL-7402 and HCC-9204. To determine cell cycle and apoptosis, FACS was carried out in the BEL-7402 and HCC-9204 cells treated with Chidamide. A decrease in the cell population at S phase and an increase in the cell population at G1 phase occurred in a dose-dependent manner. In addition, Chidamide induced apoptosis and up-regulated p21 mRNA expression. These results suggest that Chidamide may arrest the cell cycle and inhibit the growth of hepatocellular carcinoma cells through up-regulation of p21. Further studies are required to clarify the antitumor activity of Chidamide in vivo and its mechanism in anticancer therapy.
Introduction
Histone acetylases (HATs) and histone deacetylases (HDACs) are a series of enzymes functioning to acetylate and deacetylate the amino-terminal lysine residues of histones, which result in the remodeling of the chromatin structures and affect the accessibility of the chromatin to transcription factors to start gene transcription. It has been known that many tumors are characterized by an imbalance of HDAC and HAT activity (1) . HDACs regulate the expression of genes regulating a broad range of cell functions, such as tumor suppression, cell cycle, differentiation and DNA repair. Hence, they are considered as an important class of targets in cancer treatment strategies, and HDAC inhibitors are becoming a new promising class of anticancer drugs (2) .
To date, four classes of HDACs have been identified, which have been grouped into three families (1) . Class I and II are inhibited by trichostatin A (TSA); class III HDACs are a family of NAD + -dependent proteins and are not sensitive to TSA; class IV has only one member, HDAC11, whose structure is homologous to class I and II. Recently, HDAC inhibitors, including TSA, sodium butyrate, suberoylanilide hydroxamic acid, depsipeptide and MS-275, are already in pre-clinical and clinical development (3) (4) (5) (6) . Although they are structurally diverse compounds, they share the potential to prevent cell cycle progression in the G1 and G2/M phases, leading to growth arrest, differentiation and/or death of cancer cells. The precise mechanism underlying cell cycle arrest or differentiation through histone acetylation is unknown, but definitely, the effect of most HDAC inhibitors on G1 arrest is closely related to the activated transcription of the cyclin-dependent kinase inhibitor p21 CIP1/WAF . To develop more candidate HDAC inhibitors for evaluation in cancer therapy, herein we present a novel HDAC inhibitor, N-(2-amino-5-fluorine benzyl)-4-[N-(pyridine-3-acrylyl) ammonia methyl] benzamide (Chidamide), which is structurally homologous to MS-275, to explore its antitumor functions in a variety of cancer cells. The data showed that Chidamide treatment inhibits the proliferation of a series of cancer cell lines. Moreover, treatment of hepatocellular cancer cells with Chidamide induced cell cycle arrest and apoptosis along with up-regulation of p21 expression. 
Materials and methods

Regents
Reverse transcription-polymerase chain reaction (RT-PCR).
The appropriately treated BEL-7402 and HCC-9204 cells were collected and resuspended in lysis buffer for RNA extraction. RT was conducted using oligo(dT) M-MLV (Moloney murine leukemia virus reverse transcriptase) according to the manufacturer's instructions. Polymerase chain reaction was carried out with a 2400 PCR machine (Perkin Elmer). The parameters for the thermal cycling of PCR were 5 min at 95˚C for 1 cycle, 45 sec at 94˚C, 45 sec at 55˚C, 45 sec at 72˚C for 32 cycles and 10 min at 72˚C for 1 cycle. PCR primers used in the experiment were as follows: tubulin (F) 5'-CTCATCACAGGCAAGGAAGAT-3' and (R) 5'-TTAAGGTAAGTGTAGGTTGGG-3'; p21
Results
Chidamide inhibits cell growth of different cancer cell lines.
We performed MTT assay to evaluate the IC 50 of Chidamide and MS-275 in ten different cell lines. In brief, the cells were exposed to drugs at different concentrations for 72 h, and cell survival rates were calculated. Chidamide effectively inhibited cell growth of the various cell lines, irrespective of p53 status (Table Ⅰ) . Following comparison of the IC 50 values between Chidamide and MS-275, these values were at similar levels in five cell lines, while in the other tested five cell lines, the IC 50 value of Chidamide was higher compared to that of MS-275 (Table Ⅰ) . To further investigate the effect of Chidamide on cell proliferation, BEL-7402 and HCC-9204 cells were treated with Chidamide at different concentrations that were a bit lower than the IC 50 value. Chidamide significantly extended the cell doubling rates according to concentration in both cell lines (Table Ⅱ) . Notably, the effect of the growth inhibition was reversible when Chidamide was replaced with medium after 24 h of treatment ( Fig. 1A and B) .
Chidamide arrests the cell cycle at G1 phase. To determine the effect of Chidamide on the cell cycle, BEL-7402 and HCC-9204 cells were exposed to Chidamide or MS-275 at a concentration close to the IC 50 for 24 h as indicated. Similar to the effect on the MS-275 cells, FACS data showed that Chidamide significantly reduced the S phase cell fraction, while inducing a marked increase in the G1 phase cell fraction in both cell lines with different p53 statuses ( Fig. 2A and B) . Furthermore, different concentrations of Chidamide or MS-275 were used to treat BEL-7402 and HCC-9204 cells for 24 h to investigate the relationship between drug dosage and cell cycle phases. As shown in Table Ⅲ , Chidamide significantly altered the number of cells in the phase fractions with an increase in dose (i.e., in BEL-7402 cells, from 34.4 to 7.4% at S fraction, and from 34.8 to 52.5% at G1 fraction). Finally, to determine the time-course effect of Chidamide on the cell cycle, BEL-7402 cells were treated with 5 µM Chidamide for 6, 12, 24 and 48 h, followed by FACS analysis (Fig. 2C) . Chidamide reduced the S phase cell fraction starting at 6 h after treatment. The reduction was observed at 24-h exposure and continued further until 48 h. However, the change in the G1 cell fraction appeared from the 12 h timepoint, which was more obvious with elapse of time. A similar effect was achieved in the MS-275-treated group (Fig. 2D ).
Chidamide induces cell apoptosis. To test the effect of Chidamide on cell apoptosis, FACS analysis was performed in BEL-7402 cells exposed to 5 µM Chidamide and HCC-9204 cells exposed to 10 µM Chidamide, for 24 and 48 h. As shown in Fig. 3 , Chidamide induced intense apoptosis in parallel with the treatment period. In BEL-7402 cells, the apoptosis rate 
Discussion
HDAC inhibitors suppress the activity of HDAC through binding to HDAC active sites. HDAC inhibitors have been categorized into four classes: hydroxamates, benzamides, short-chain fatty acids and cyclic peptides (4). MS-275 is an artificial benzamide derivative with anticancer effects on various types of cancer, such as lung (7), ovarian (8) and colorectal cancer (9) . Chidamide, a structural analog of MS-275, is a novel HDAC inhibitor developed by Chipscreen Biosciences (Shenzhen, China). The drug is currently in NDA-directed clinical studies for relapsed T cell lymphoma at multi-centers across China and phase I in the US as well. Compared to MS-275, Chidamide is more stable and can be stored at room temperature. Moreover, Chidamide has a longer half-life and is less toxic in vivo than MS-275 (10). -, cells did not achieve a 2-fold increase in number during the 7 days of observation. BEL-7402 and HCC-9204 cells were treated with either medium or Chidamide at indicated concentrations and time-points, and then subjected to MTT assay. To test the reversibility of the effect of Chidamide, the drug in one of the groups with a high concentration of Chidamide was replaced with medium after 24 h of treatment. Cell number was determined by trypan blue exclusion, and then a cell growth curve was plotted and the cell doubling time was calculated. In the present study, the effect of Chidamide on cell growth was evaluated in ten solid tumor cell lines. As shown in Table Ⅰ , the IC 50 of Chidamide and MS-275 were quite similar in half of the studied cell lines. The IC 50 of Chidamide was significantly different to that of MS-275 in the other five cell lines, but they were both at µM concentrations. This indicates that Chidamide exhibits broad anticancer effects in vitro, particularly in lung, breast and pancreatic cancer cell lines.
Moreover, to explore whether Chidamide markedly inhibited cell growth, growth curves were plotted for the BEL-7402 and HCC-9204 cells treated with Chidamide. As shown in Table Ⅱ , Chidamide significantly prolonged the cell doubling time and induced cell death at the dose of IC 50 . Meanwhile, Chidamide reduced the cell population in the S phase, during which DNA synthesis occurs, resulting in G1 phase arrest in cancer cells. We also studied the reversibility of cell growth after drug treatment by a growth curve experiment. Cancer cells recovered to normal growth after replacing Chidamide with medium, suggesting that the effect of Chidamide on cell growth inhibition was reversible. Fournel et al demonstrated that HCT116 cell growth resumed after the removal of another MS-275 analog, and acetylated H3 and H4 significantly decreased (11), supporting our data in the present study. In addition, this suggests that the histone acetylation status was closely related to cell growth and viability. Moreover, the combination between HDAC inhibitors and HDAC was a reversible reaction, and HDAC restores activity after removal of inhibitors (12) .
Epigenetic modification and chromatin remodeling is the key event during carcinogenesis by upsetting the transcriptional balance between oncogenes and tumor-suppressing genes. The mechanism of the antitumor effect of Chidamide has not yet been clarified. Liu et al showed that Chidamide increased the accumulation of acetylated histone H3 in colon cancer cells (10) . Alternatively, it also increased the acetylation levels of non-histone protein. Herein, we explored the relationship between p21 and Chidamide. It has been known that HDAC regulates the acetylation levels of p21 in two ways (13) . One way is to change p53 promoter acetylation levels via its deacetylation effect. Therefore, the activity of p53 is suppressed and expression of p21 is reduced. Another is p53-independent, by which HDAC inhibits histone acetylation levels and makes DNA more closely bind to histone. Consequently, transcriptional factors, such as sp1 and E2A, could not combine with binding sites on the promoter region of p21 which leads to transcription suppression. Notably, the p53-independent pathway is dominant in p21 gene expression up-regulated by HDAC inhibitors (14, 15) . Our data showed that Chidamide increased p21 mRNA levels in both BEL-7402 cells with wild-type p53 and in HCC-9204 cells with mutant p53 (Fig. 4) . In addition, the IC 50 between wild-type p53 cell lines and mutant p53 cell lines was not significantly different, which also implies that p21 expression is mainly regulated by an p53-independent pathway.
HDAC inhibitors regulate cell cycle process. For example, MS-275 may decrease the proportion of cells in S phase and increase the proportion of cells in G1 phase, which causes G1 phase arrest (16, 17) . Similarly, TSA also induces G1 arrest (18) . We evaluated the effect of Chidamide on the cell cycle in BEL-7402 and HCC-9204 cells. Chidamide reduced the percentage of cells in the S phase and arrested cells at G1 phase, but the change in G2 phase was not consistent, with a slightly increasing trend. MS-275, as a reference component, caused similar results in this study. As a cell cycle-dependent kinase inhibitor, P21 closely integrates with kinases of G1 and S phase, such as cyclin E/Cdk2, cyclin D/Cdk4 and cyclin A/ Cdk2, blocking transition from G1 to S phase. Meanwhile, its interation with kinases in G2 phase is weaker.
Data in the present study suggest that the effect of Chidamide on the cell cycle is dose-and time-dependent. Exposure to Chidamide at less than IC 50 dose and less than 24 h did not induce a significant change in cell cycle of BEL-7402 cells (Fig. 2C) . Notably, p21 mRNA levels displayed a similar trend evaluated by RT-PCR. This again indicates that p21 is closely related to the cell cycle arrest induced by Chidamide. However, P21 is not an exclusive factor involved in cell cycle arrest resulting from Chidamide. Other mechanisms may play a role in this process.
Chidamide induces cell apoptosis, the mechanism of which is not very clear. Our data showed that cell apoptosis began to occur at 24 h after Chidamide treatment and became more obvious at 48 h, which has the same trend with p21 mRNA expression, except for 12-24 h time lag. It has been known that MS-275-induced apoptosis is largely independent of the extrinsic/receptor-mediated pathway and mainly involves engagement of the intrinsic/mitochondrial-related pathway (19) . U937 cells stably expressing ectopic Bcl-2 or Bcl-XL significantly protected cells from MS-275-induced death. Liu et al reported that Chidamide-treated colon cancer cells exhibited swollen mitochondria and increased cleavage of caspase-3 and PARP (10) . It is supposed that the mitochondrial-mediated pathway also plays a critical role in apoptosis caused by Chidamide, but the mechanism requires investigation. Collectively, the results described indicate that Chidamide is a promising anticancer agent with significant effect on growth inhibition of various cell lines. As an analog of Chidamide, MS-275 selectively inhibits HDAC1 and 9, 2 and 3, but has little effect on HDAC4, 6, 7 and 8 (20) . To date, no data on the selectivity of Chidamide has been found, and this requires clarified. Meanwhile, to make Chidamide available at the bedside of patients, the anticancer activity of Chidamide alone as well as in combination with chemotherapy drugs in vivo, and the underlying mechanism are the focus of further investigation.
